BE waiver for tablet after reducing % of API [Dissolution / BCS / IVIVC]

posted by Helmut Homepage – Vienna, Austria, 2009-05-19 17:25 (6238 d 08:55 ago) – Posting: # 3707
Views: 7,104

Dear Gary,

remember that both the manufacturing process and the analytical method are subjected to some variability. If you have demonstrated BE to the innovator already in vivo, I don't get the point of reformulating. Can you give us a rationale?

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
151 visitors (0 registered, 151 guests [including 11 identified bots]).
Forum time: 02:20 CEST (Europe/Vienna)

“Data! Data! Data!” he cried impatiently.
“I can’t make bricks without clay!”    Arthur Conan Doyle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5